Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

33-047

Sigma-Aldrich

PI 3-Kinase 3-step HTRF® Assay

The PI 3-Kinase 3-Step HTRF Assay is a high-performance assay kit that provides a universal method for testing all Class I PI3-Kinases in a homogeneous format.

Synonym(e):

3-Step HTRF Assay, PI 3-Kinase Assay

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

UNSPSC-Code:
12161503
eCl@ss:
32161000
NACRES:
NA.84

Qualitätsniveau

Speziesreaktivität

human, mouse

Hersteller/Markenname

HTRF®
Upstate®

Methode(n)

activity assay: suitable (kinase)

NCBI-Hinterlegungsnummer

UniProt-Hinterlegungsnummer

Nachweisverfahren

fluorometric (HTRF)

Versandbedingung

dry ice

Angaben zum Gen

human ... PIK3CA(5290)

Allgemeine Beschreibung

Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α (PIK3CA) gene is mapped to human chromosome 3q26.32. This gene codes for the catalytic subunit p110α of class IA PI3-kinase. PI3K signaling pathways regulate various cellular activities and properties including proliferation, survival, apoptosis, motility, and morphology. Mutation or overexpression of the PIK3CA gene is implicated in the development of various human solid tumors including head and neck cancers or pharyngeal cancer and ovarian cancer.

Anwendung

PI 3-Kinase 3-step HTRF® Assay has been used to determine the in vitro inhibitory potencies of phosphatidylinositol 3-kinase (PI3K) δ inhibitors such as MSD-496486311, MSD126796721, idelalisib, and duvelisib across PI3K α, β, γ, and δ isoforms.

Biochem./physiol. Wirkung

Target Sub-Family: PI3K/PI4K

Verpackung

Kit capacity: 10,000 wells

Komponenten

4X Reaction Buffer

PIP2 (substrate, 1mM stock)

DM A Reaction Buffer

DM B Reaction Buffer

DM C Reaction Buffer

BPIP3

Stop Reagent

Lagerung und Haltbarkeit

12 months at -70°C

Sonstige Hinweise

Research Category
Apoptosis & Cancer
Research Sub Category
Oncology

Rechtliche Hinweise

HTRF is a registered trademark of Cis Bio International
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany

Haftungsausschluss

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Piktogramme

Exclamation mark

Signalwort

Warning

H-Sätze

Gefahreneinstufungen

Eye Irrit. 2

Lagerklassenschlüssel

12 - Non Combustible Liquids

WGK

WGK 2

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Robbie L McLeod et al.
The Journal of pharmacology and experimental therapeutics, 369(2), 223-233 (2019-02-26)
We leveraged a clinical pharmacokinetic (PK)/pharmacodynamics (PD)/efficacy relationship established with an oral phosphatidylinositol 3-kinase (PI3K)δ inhibitor (Idelalisib) in a nasal allergen challenge study to determine whether a comparable PK/PD/efficacy relationship with PI3Kδ inhibitors was observed in preclinical respiratory models of
Andreas G Bader et al.
Nature reviews. Cancer, 5(12), 921-929 (2005-12-13)
There have long been indications of a role for PI3K (phosphatidylinositol 3-kinase) in cancer pathogenesis. Experimental data document a requirement for deregulation of both transcription and translation in PI3K-mediated oncogenic transformation. The recent discoveries of cancer-specific mutations in PIK3CA, the
Wanglong Qiu et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 12(5), 1441-1446 (2006-03-15)
Recent studies have reported high frequencies of somatic mutations in the phosphoinositide-3-kinase catalytic alpha (PIK3CA) gene in several human solid tumors. Although gene amplifications of PIK3CA have been reported in head and neck squamous cell carcinoma (HNSCC), small mutation of

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.